"# Grabowski GA, Kacena K, Cole JA, Hollak CE, Zhang L, Yee J, Mistry PK, Zimran A, Charrow J, vom Dahl S: Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet Med. 2009 Feb;11(2):92-100. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19265748"@en . "3.6-10.4 min"@en . . . . "37228-64-1"@en . . . " "@en . . . . . . "Alglucerase catalyzes the hydrolysis of the glycolipid, glucocerebroside, to glucose and ceramide as part of the normal degradation pathway for membrane lipids."@en . "Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues"@en . "For the treatment of Gaucher's disease (deficiency in glucocerebrosidase)"@en . . "Alglucerase"@en . . "approved"@en . "* 49.4 to 282.1 mL/kg"@en . . . . . . . . . "Humans and other mammals"@en . . .